FDA Questions Constitutionality Of Proposed CIR Bridge, A Blow To CMA Bill

The Cosmetic Modernization Amendments of 2015 is touted by small business as a more appropriately sized update to the regulatory framework than the front-running PCPSA. However, some provisions seen as vital are absent from the bill, while its call for FDA to accept CIR safety decisions could be deemed unconstitutional, an FDA official suggests in a letter to Senate HELP Committee Chair Lamar Alexander.

US Constitution

More from Ingredients & Safety

More from HBW Insight